Effect of Skin-To-Skin Contact During Caesarean Section on Pain and Stress in Newborns: A Randomized Controlled Trial.

Nurs OpenOct 1, 2026
Clinical ResearchObstetrics & GynecologyPediatrics

Seda Yazici Yel, Sena Dilek Aksoy

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the impact of skin-to-skin contact during caesarean sections on neonatal pain and stress during the first intramuscular injection. Conducted with 60 healthy term newborns, results indicated that the skin-to-skin contact group had significantly lower pain and stress scores during the injection, with a mean difference of -2.633 (95% CI: -3.135 to -2.132, p < 0.001).

Key findings

  • Skin-to-skin contact resulted in lower ALPS-Neo scores during the first injection compared to routine care.
  • The mean difference in ALPS-Neo scores during the injection was -2.633 (95% CI: -3.135 to -2.132, p < 0.001).
  • A large standardized effect size of Hedges' g = -2.68 was observed for the intervention group.

Why it matters

The findings suggest that skin-to-skin contact can be an effective non-pharmacological approach to alleviate pain and stress in newborns during routine procedures, enhancing neonatal comfort.

Source

PubMed · PMID 42830547

Published in Nurs Open. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.